Microsoft selbst warnt vor der Verwendung von Internet Explorer, da er nicht mehr den neuesten Web- und Sicherheitsstandards entspricht. Wir können daher nicht garantieren, dass die Seite im Internet Explorer in vollem Umfang funktioniert. Nutze bitte Chrome oder Firefox.

Better Buy: Gilead Sciences vs. Biogen

TheMotleyFool

0 0

Plodding and plunging. That's maybe the best way to summarize 2019 so far for Gilead Sciences (NASDAQ: GILD) and Biogen (NASDAQ: BIIB), respectively.

Gilead Sciences continues to plod along with its stock range-bound throughout the year. The big biotech did, however, return to revenue growth after a long stretch of declining sales. Biogen, meanwhile, saw its shares plunge in March after experimental Alzheimer's disease drug aducanumab flopped in late-stage clinical testing.

Which of these biotech stocks is the better pick for long-term investors now? Here's how Gilead and Biogen stack up against each other.

Source Fool.com

Like: 0

GILD

Teilen